Given the increasing evidence for EZH2 involvement in NB, especially in tandem with MYCN (9, 10, 42, 43), there is clearly a rationale for deploying G9a and EZH2 inhibitors together for the treatment of NB. The gene discussed is EZH2; the disease is neuroblastoma.